Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN del PF-04691502 non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown XL147 non-small cell lung carcinoma not applicable detail...
PTEN loss Pictilisib non-small cell lung carcinoma sensitive detail...
KRAS mutant Selumetinib + Docetaxel non-small cell lung carcinoma no benefit detail...
Unknown unknown BMS-690514 non-small cell lung carcinoma not applicable detail...
Unknown unknown Itraconazole + Pemetrexed non-small cell lung carcinoma not applicable detail...
Unknown unknown Motesanib + Paclitaxel non-small cell lung carcinoma not applicable detail...
Unknown unknown Motesanib + Carboplatin non-small cell lung carcinoma not applicable detail...
ERBB2 mutant Neratinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Ramucirumab + Paclitaxel + Carboplatin non-small cell lung carcinoma not applicable detail...
Unknown unknown Axitinib + Radiotherapy non-small cell lung carcinoma not applicable detail...
BRAF Y472C Dasatinib non-small cell lung carcinoma sensitive detail...
BRAF G466V Dasatinib non-small cell lung carcinoma sensitive detail...
BRAF V600E Vemurafenib non-small cell lung carcinoma sensitive detail...
BRAF V600E Dabrafenib non-small cell lung carcinoma sensitive detail...
TP53 P72R Camptosar + Cisplatin non-small cell lung carcinoma sensitive detail...
MET amp Selumetinib non-small cell lung carcinoma sensitive detail...
MET amp BEZ235 non-small cell lung carcinoma sensitive detail...
MET amp Selumetinib + BEZ235 non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK G1202R Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK S1206Y Crizotinib non-small cell lung carcinoma resistant detail...
Unknown unknown Adavosertib non-small cell lung carcinoma not applicable detail...
Unknown unknown Temsirolimus non-small cell lung carcinoma not applicable detail...
Unknown unknown Vandetanib non-small cell lung carcinoma not applicable detail...
RET act mut Ponatinib non-small cell lung carcinoma sensitive detail...
KRAS G12C Cobimetinib non-small cell lung carcinoma sensitive detail...
KRAS G12X Cobimetinib non-small cell lung carcinoma sensitive detail...
KRAS mut + GATA2 wild-type bortezomib + fasudil non-small cell lung carcinoma sensitive detail...
Unknown unknown Ramucirumab + Docetaxel non-small cell lung carcinoma not applicable detail...
Unknown unknown Everolimus + Erlotinib non-small cell lung carcinoma not applicable detail...
Unknown unknown Pemetrexed + Sirolimus non-small cell lung carcinoma not applicable detail...
Unknown unknown Lenvatinib + Carboplatin + Paclitaxel non-small cell lung carcinoma not applicable detail...
Unknown unknown Merestinib non-small cell lung carcinoma not applicable detail...
Unknown unknown Abemaciclib non-small cell lung carcinoma not applicable detail...
ALK rearrange SRC pos Saracatinib + Ceritinib non-small cell lung carcinoma sensitive detail...
ALK positive Belizatinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Ficlatuzumab + Gefitinib non-small cell lung carcinoma not applicable detail...
MET positive Onartuzumab + Erlotinib non-small cell lung carcinoma conflicting detail...
ALK positive Ensartinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Linifanib + Paclitaxel + Carboplatin non-small cell lung carcinoma not applicable detail...
PDGFRA amp Sunitinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Bevacizumab + Carboplatin + Paclitaxel non-small cell lung carcinoma not applicable detail...
EML4-ALK ALK G1269A Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK G1269A Ceritinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK L1196M Ceritinib non-small cell lung carcinoma sensitive detail...
Unknown unknown A-1331852 + Docetaxel non-small cell lung carcinoma not applicable detail...
EML4-ALK Sirolimus + X-396 non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK G1202R Ceritinib non-small cell lung carcinoma resistant detail...
KRAS mutant Sorafenib non-small cell lung carcinoma sensitive detail...
KRAS G12C Sorafenib non-small cell lung carcinoma sensitive detail...
Unknown unknown Alisertib non-small cell lung carcinoma not applicable detail...
KRAS G12C Selumetinib + Docetaxel non-small cell lung carcinoma predicted - sensitive detail...
KRAS G12V Selumetinib + Docetaxel non-small cell lung carcinoma predicted - sensitive detail...
PTPN11 act mut Refametinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK V1180L Lorlatinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK L1196M Lorlatinib non-small cell lung carcinoma sensitive detail...
EML4-ALK Lorlatinib non-small cell lung carcinoma sensitive detail...
KRAS mutant Panulisib non-small cell lung carcinoma sensitive detail...
KRAS mutant RO4987655 non-small cell lung carcinoma sensitive detail...
KRAS G12C SML-10-70-1 non-small cell lung carcinoma sensitive detail...
ALK rearrange Crizotinib non-small cell lung carcinoma sensitive detail...
ERBB2 mutant AV-412 non-small cell lung carcinoma sensitive detail...
CDKN2A loss Palbociclib non-small cell lung carcinoma sensitive detail...
ALK fusion Alectinib non-small cell lung carcinoma sensitive detail...
ALK fusion Brigatinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK L1196M Brigatinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK C1156Y Ceritinib non-small cell lung carcinoma conflicting detail...
KRAS Q61H Pictilisib non-small cell lung carcinoma resistant detail...
KRAS Q61H CUDC-907 non-small cell lung carcinoma sensitive detail...
KRAS G12S Gedatolisib non-small cell lung carcinoma sensitive detail...
NRAS Q61K Gedatolisib non-small cell lung carcinoma decreased response detail...
TP53 R158G Gedatolisib non-small cell lung carcinoma sensitive detail...
STK11 mutant Gedatolisib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK G1269A Lorlatinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK I1171T Lorlatinib non-small cell lung carcinoma sensitive detail...
Unknown unknown BMS-906024 non-small cell lung carcinoma not applicable detail...
ALK rearrange Ceritinib + Crizotinib non-small cell lung carcinoma sensitive detail...
ALK rearrange ALK mut Ceritinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK V1180L Alectinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK V1180L Crizotinib non-small cell lung carcinoma resistant detail...
KRAS G12C CID1067700 non-small cell lung carcinoma sensitive detail...
ALK rearrange Ceritinib non-small cell lung carcinoma sensitive detail...
ALK rearrange Brigatinib non-small cell lung carcinoma sensitive detail...
ALK rearrange Alectinib non-small cell lung carcinoma sensitive detail...
ALK rearrange Ensartinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Everolimus non-small cell lung carcinoma not applicable detail...
Unknown unknown Cediranib + Gemcitabine + Cisplatin non-small cell lung carcinoma not applicable detail...
Unknown unknown AXL1717 non-small cell lung carcinoma not applicable detail...
Unknown unknown XL228 non-small cell lung carcinoma not applicable detail...
Unknown unknown Conatumumab + Ganitumab non-small cell lung carcinoma not applicable detail...
EML4-ALK TAE226 non-small cell lung carcinoma sensitive detail...
BRAF G469A TAE226 non-small cell lung carcinoma sensitive detail...
BRAF G466V TAE226 non-small cell lung carcinoma sensitive detail...
KRAS G12S TAE226 non-small cell lung carcinoma sensitive detail...
MET amp TAE226 non-small cell lung carcinoma sensitive detail...
SRC amp Derazantinib non-small cell lung carcinoma sensitive detail...
FGFR1 amp FF-284 non-small cell lung carcinoma sensitive detail...
TP53 R248W APR-246 + Cisplatin non-small cell lung carcinoma sensitive detail...
TP53 R273H APR-246 + Cisplatin non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK G1269A Alectinib non-small cell lung carcinoma sensitive detail...
BRAF V600E Navitoclax + Vemurafenib non-small cell lung carcinoma sensitive detail...
BRAF V600E Trametinib + Navitoclax non-small cell lung carcinoma sensitive detail...
BRAF V600E Trametinib + TW-37 non-small cell lung carcinoma sensitive detail...
BRAF V600E Vemurafenib + TW-37 non-small cell lung carcinoma sensitive detail...
KRAS G12S Trametinib + Navitoclax non-small cell lung carcinoma sensitive detail...
KRAS G12C Trametinib + Navitoclax non-small cell lung carcinoma sensitive detail...
KRAS G12S Trametinib + TW-37 non-small cell lung carcinoma sensitive detail...
KRAS G12C Trametinib + TW-37 non-small cell lung carcinoma sensitive detail...
TP53 wild-type CEP-8983 + Cisplatin non-small cell lung carcinoma sensitive detail...
TP53 mutant CEP-8983 + Cisplatin non-small cell lung carcinoma sensitive detail...
Unknown unknown SH-1242 non-small cell lung carcinoma not applicable detail...
KRAS mutant SH-1242 non-small cell lung carcinoma sensitive detail...
Unknown unknown PRN1371 non-small cell lung carcinoma not applicable detail...
Unknown unknown Docetaxel + Plinabulin non-small cell lung carcinoma not applicable detail...
BRAF L485_P490delinsY LY3009120 non-small cell lung carcinoma sensitive detail...
BRAF L485_P490delinsY Trametinib non-small cell lung carcinoma sensitive detail...
BRAF L485_P490delinsY Vemurafenib non-small cell lung carcinoma resistant detail...
ROS1 rearrange Crizotinib non-small cell lung carcinoma sensitive detail...
Unknown unknown TVB-2640 non-small cell lung carcinoma not applicable detail...
EML4-ALK ALK I1171S Alectinib non-small cell lung carcinoma resistant detail...
KRAS mut STK11 mut PKI-402 non-small cell lung carcinoma sensitive detail...
ATM loss AZD6738 + Cisplatin non-small cell lung carcinoma sensitive detail...
EML4-ALK Entrectinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK C1156Y Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK C1156Y Lorlatinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK C1156Y Luminespib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK C1156Y ALK L1198F Lorlatinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK C1156Y ALK L1198F Crizotinib non-small cell lung carcinoma sensitive detail...
Unknown unknown ST7612AA1 non-small cell lung carcinoma not applicable detail...
KDR amp Vandetanib non-small cell lung carcinoma no benefit detail...
Unknown unknown PF-03446962 non-small cell lung carcinoma not applicable detail...
Unknown unknown Afatinib + Nimotuzumab non-small cell lung carcinoma not applicable detail...
KRAS mutant BI2536 non-small cell lung carcinoma sensitive detail...
KRAS mutant Volasertib non-small cell lung carcinoma sensitive detail...
CDH1 over exp BI2536 non-small cell lung carcinoma resistant detail...
CDH1 over exp Volasertib non-small cell lung carcinoma resistant detail...
KRAS mutant XMT-1536 non-small cell lung carcinoma predicted - sensitive detail...
KRAS Q61K XL147 non-small cell lung carcinoma sensitive detail...
KRAS G12S STK11 inact mut XL147 non-small cell lung carcinoma sensitive detail...
KRAS Q61K XL147 + Carboplatin non-small cell lung carcinoma sensitive detail...
EML4-ALK Crizotinib non-small cell lung carcinoma sensitive detail...
EML4-ALK Ceritinib non-small cell lung carcinoma sensitive detail...
EML4-ALK Alectinib non-small cell lung carcinoma sensitive detail...
CBLC over exp N/A non-small cell lung carcinoma not applicable detail...
Unknown unknown Nivolumab non-small cell lung carcinoma not applicable detail...
Unknown unknown BAY1161909 + Paclitaxel non-small cell lung carcinoma not applicable detail...
Unknown unknown BAY1217389 + Paclitaxel non-small cell lung carcinoma not applicable detail...
KRAS mutant Paclitaxel + TVB-2640 non-small cell lung carcinoma predicted - sensitive detail...
KRAS mutant TVB-2640 non-small cell lung carcinoma predicted - sensitive detail...
KRAS mutant Trametinib non-small cell lung carcinoma sensitive detail...
ALK fusion Lorlatinib non-small cell lung carcinoma sensitive detail...
ROS1 fusion Lorlatinib non-small cell lung carcinoma sensitive detail...
ALK fusion ALK G1202R Lorlatinib non-small cell lung carcinoma sensitive detail...
MET act mut Crizotinib non-small cell lung carcinoma predicted - sensitive detail...
FGFR1 amp AZD4547 non-small cell lung carcinoma sensitive detail...
ERBB2 amp Afatinib non-small cell lung carcinoma sensitive detail...
ERBB2 G776delinsVC Afatinib non-small cell lung carcinoma conflicting detail...
ERBB2 G776delinsVC Gefitinib non-small cell lung carcinoma resistant detail...
RET fusion Vandetanib non-small cell lung carcinoma sensitive detail...
ALK neg ROS1 pos Crizotinib non-small cell lung carcinoma sensitive detail...
EZH2 over exp JQEZ5 non-small cell lung carcinoma sensitive detail...
ALK positive Crizotinib + Onalespib non-small cell lung carcinoma no benefit detail...
MET positive Capmatinib non-small cell lung carcinoma sensitive detail...
MET exon 14 Capmatinib non-small cell lung carcinoma sensitive detail...
MET amp Capmatinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Carboplatin + Demcizumab + Pemetrexed non-small cell lung carcinoma not applicable detail...
Unknown unknown Vantictumab non-small cell lung carcinoma not applicable detail...
KRAS mutant BGB-283 non-small cell lung carcinoma predicted - sensitive detail...
KRAS mutant Abemaciclib non-small cell lung carcinoma sensitive detail...
CDKN2A loss KRAS wild-type Abemaciclib non-small cell lung carcinoma sensitive detail...
Unknown unknown Sorafenib non-small cell lung carcinoma no benefit detail...
KRAS wild-type Sorafenib non-small cell lung carcinoma no benefit detail...
MET amp EMD 1214063 non-small cell lung carcinoma sensitive detail...
KRAS mutant Erlotinib non-small cell lung carcinoma no benefit detail...
KRAS mutant Erlotinib + MK2206 non-small cell lung carcinoma no benefit detail...
KRAS mutant MK2206 + Selumetinib non-small cell lung carcinoma no benefit detail...
Unknown unknown LY3164530 non-small cell lung carcinoma not applicable detail...
KRAS mutant Carboplatin + Erlotinib + Paclitaxel non-small cell lung carcinoma no benefit detail...
KRAS wild-type Erlotinib non-small cell lung carcinoma sensitive detail...
KRAS G12C ARS-853 non-small cell lung carcinoma sensitive detail...
BRAF L485Y GDC0879 non-small cell lung carcinoma resistant detail...
KRAS mutant GDC0879 non-small cell lung carcinoma resistant detail...
BRAF wild-type KRAS Q61K GDC0879 non-small cell lung carcinoma resistant detail...
BRAF wild-type GDC0879 non-small cell lung carcinoma resistant detail...
BRAF wild-type KRAS G12C GDC0879 non-small cell lung carcinoma resistant detail...
BRAF wild-type KRAS G12V GDC0879 non-small cell lung carcinoma resistant detail...
BRAF L597V NRAS Q61K AZ628 non-small cell lung carcinoma sensitive detail...
BRAF L597V NRAS Q61K TAK-632 non-small cell lung carcinoma sensitive detail...
BRAF G466V TAK-632 non-small cell lung carcinoma sensitive detail...
BRAF L597V NRAS Q61K PLX7904 non-small cell lung carcinoma decreased response detail...
BRAF L597V NRAS Q61K Vemurafenib non-small cell lung carcinoma decreased response detail...
BRAF G466V Vemurafenib non-small cell lung carcinoma decreased response detail...
BRAF L597V NRAS Q61K Dabrafenib non-small cell lung carcinoma decreased response detail...
TP53 wild-type AMG 232 non-small cell lung carcinoma sensitive detail...
TP53 wild-type AMG 232 + Cisplatin non-small cell lung carcinoma sensitive detail...
TP53 wild-type AMG 232 + Carboplatin non-small cell lung carcinoma sensitive detail...
NRAS Q61K Pimasertib non-small cell lung carcinoma sensitive detail...
KRAS G12V Pimasertib non-small cell lung carcinoma sensitive detail...
NRAS Q61K Everolimus + Pimasertib non-small cell lung carcinoma sensitive detail...
KRAS G12S Everolimus + Pimasertib non-small cell lung carcinoma sensitive detail...
NRAS Q61K Pimasertib + Sorafenib non-small cell lung carcinoma sensitive detail...
KRAS G12S Pimasertib + Sorafenib non-small cell lung carcinoma sensitive detail...
NRAS Q61K Pimasertib + Regorafenib non-small cell lung carcinoma sensitive detail...
KRAS G12S Pimasertib + Regorafenib non-small cell lung carcinoma sensitive detail...
Unknown unknown Bavituximab + Docetaxel non-small cell lung carcinoma no benefit detail...
KRAS mutant PF-04691502 non-small cell lung carcinoma predicted - sensitive detail...
FGFR1 amp PRN1371 non-small cell lung carcinoma sensitive detail...
FGFR2 amp PRN1371 non-small cell lung carcinoma sensitive detail...
FGFR3 amp PRN1371 non-small cell lung carcinoma sensitive detail...
ALK rearrange Nivolumab non-small cell lung carcinoma no benefit detail...
ALK rearrange Pembrolizumab non-small cell lung carcinoma no benefit detail...
ALK rearrange Durvalumab non-small cell lung carcinoma no benefit detail...
ALK rearrange Atezolizumab non-small cell lung carcinoma no benefit detail...
FGFR1 amp RO4987655 non-small cell lung carcinoma no benefit detail...
FGFR1 amp RO5126766 non-small cell lung carcinoma no benefit detail...
FGFR1 amp Selumetinib non-small cell lung carcinoma no benefit detail...
Unknown unknown CEP-32496 non-small cell lung carcinoma not applicable detail...
Unknown unknown Axitinib non-small cell lung carcinoma not applicable detail...
Unknown unknown Lenvatinib non-small cell lung carcinoma not applicable detail...
Unknown unknown Nintedanib + Docetaxel non-small cell lung carcinoma not applicable detail...
ALK rearrange MAP2K1 K57N Ceritinib + Selumetinib non-small cell lung carcinoma sensitive detail...
MET amp KTN0073-IgG2 non-small cell lung carcinoma sensitive detail...
MET del exon14 KTN0073-IgG1 non-small cell lung carcinoma sensitive detail...
KRAS Q61K BI-847325 non-small cell lung carcinoma sensitive detail...
KRAS mutant KPT-185 non-small cell lung carcinoma sensitive detail...
Unknown unknown SBI-0206965 + AZD8055 non-small cell lung carcinoma not applicable detail...
Unknown unknown MLN0128 + SBI-0206965 non-small cell lung carcinoma not applicable detail...
Unknown unknown Sirolimus + SBI-0206965 non-small cell lung carcinoma not applicable detail...
Unknown unknown Atezolizumab non-small cell lung carcinoma not applicable detail...
EML4-ALK Afatinib + Alectinib non-small cell lung carcinoma sensitive detail...
FGFR1 amp E7090 non-small cell lung carcinoma sensitive detail...
MET amp SGX523 non-small cell lung carcinoma sensitive detail...
MET amp Dasatinib non-small cell lung carcinoma predicted - sensitive detail...
MET amp PP-121 non-small cell lung carcinoma predicted - sensitive detail...
MET amp Ganetespib non-small cell lung carcinoma predicted - sensitive detail...
MET amp Alvespimycin non-small cell lung carcinoma predicted - sensitive detail...
MET amp Crizotinib non-small cell lung carcinoma sensitive detail...
FGFR1 amp NGI-1 non-small cell lung carcinoma predicted - sensitive detail...
EML4-ALK Brigatinib non-small cell lung carcinoma sensitive detail...
Unknown unknown NU7441 + Radiotherapy non-small cell lung carcinoma not applicable detail...
Unknown unknown Gemcitabine + SRA737 non-small cell lung carcinoma not applicable detail...
Unknown unknown Ganetespib + Radiotherapy non-small cell lung carcinoma not applicable detail...
Unknown unknown Dasatinib non-small cell lung carcinoma not applicable detail...
Unknown unknown Carboplatin + Ganetespib + Paclitaxel + Radiotherapy non-small cell lung carcinoma conflicting detail...
Unknown unknown Cetuximab + Cisplatin + Vinorelbine non-small cell lung carcinoma no benefit detail...
BRAF G469A Trametinib + Dabrafenib non-small cell lung carcinoma sensitive detail...
BRAF mutant Trametinib + Dabrafenib non-small cell lung carcinoma predicted - sensitive detail...
BRAF G469V Sorafenib non-small cell lung carcinoma sensitive detail...
BRAF G469A Vemurafenib non-small cell lung carcinoma resistant detail...
BRAF G469A Trametinib non-small cell lung carcinoma sensitive detail...
BRAF G469A Trametinib + Vemurafenib non-small cell lung carcinoma conflicting detail...
ROS1 rearrange NPS-1034 non-small cell lung carcinoma sensitive detail...
ROS1 rearrange Cabozantinib non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown TAS-116 + Radiotherapy non-small cell lung carcinoma not applicable detail...
KRAS mutant Aurora Kinase Inhibitor II non-small cell lung carcinoma sensitive detail...
STK11 inact mut Trametinib non-small cell lung carcinoma sensitive detail...
STK11 Q37* Trametinib non-small cell lung carcinoma sensitive detail...
STK11 E199* Trametinib non-small cell lung carcinoma sensitive detail...
STK11 W332* Trametinib non-small cell lung carcinoma sensitive detail...
STK11 dec exp Trametinib non-small cell lung carcinoma sensitive detail...
STK11 K48fs Trametinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Antroquinonol non-small cell lung carcinoma not applicable detail...
Unknown unknown Sunitinib non-small cell lung carcinoma not applicable detail...
Unknown unknown Regorafenib non-small cell lung carcinoma not applicable detail...
Unknown unknown Aflibercept + Docetaxel non-small cell lung carcinoma not applicable detail...
Unknown unknown Pazopanib non-small cell lung carcinoma not applicable detail...
Unknown unknown Metformin non-small cell lung carcinoma not applicable detail...
ERBB2 mutant Pyrotinib non-small cell lung carcinoma sensitive detail...
ROS1 fusion DS6051b non-small cell lung carcinoma predicted - sensitive detail...
MET positive Emibetuzumab + Erlotinib non-small cell lung carcinoma sensitive detail...
MET del exon14 Onartuzumab non-small cell lung carcinoma sensitive detail...
MET positive Telisotuzumab vedotin non-small cell lung carcinoma sensitive detail...
MET over exp Telisotuzumab vedotin non-small cell lung carcinoma sensitive detail...
MET amp over exp Altiratinib non-small cell lung carcinoma sensitive detail...
ERBB2 mutant Afatinib non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 mutant Trastuzumab non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 exon 20 ins Afatinib non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 exon 20 ins Trastuzumab non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown TMU-35435 non-small cell lung carcinoma not applicable detail...
Unknown unknown Decitabine + TMU-35435 non-small cell lung carcinoma not applicable detail...
Unknown unknown Chiauranib non-small cell lung carcinoma not applicable detail...
Unknown unknown INCB059872 non-small cell lung carcinoma not applicable detail...
ALK positive Entrectinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Cabozantinib non-small cell lung carcinoma not applicable detail...
Unknown unknown Cabozantinib + Erlotinib non-small cell lung carcinoma conflicting detail...
RET rearrange Alectinib non-small cell lung carcinoma predicted - sensitive detail...
ALK rearrange ALK I1171N Alectinib non-small cell lung carcinoma predicted - resistant detail...
ALK rearrange ALK G1202R Alectinib non-small cell lung carcinoma predicted - resistant detail...
ROS1 rearrange Entrectinib non-small cell lung carcinoma sensitive detail...
STK11 E57fs Trametinib non-small cell lung carcinoma sensitive detail...
Unknown unknown DCBCI0901 non-small cell lung carcinoma not applicable detail...
Unknown unknown Carboplatin + Paclitaxel + Veliparib non-small cell lung carcinoma not applicable detail...
Unknown unknown Ro 31-8220 non-small cell lung carcinoma not applicable detail...
KRAS mut STK11 inact mut SAR245409 non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK F1245C Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK F1245C Ceritinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Docetaxel + Trametinib non-small cell lung carcinoma not applicable detail...
KRAS mutant Docetaxel + Trametinib non-small cell lung carcinoma predicted - sensitive detail...
KRAS G12C Docetaxel + Trametinib non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown Pemetrexed + GSK1120212 non-small cell lung carcinoma not applicable detail...
KRAS mutant Pemetrexed + GSK1120212 non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown SIM-89 non-small cell lung carcinoma not applicable detail...
RET rearrange Cabozantinib non-small cell lung carcinoma sensitive detail...
RET rearrange Vandetanib non-small cell lung carcinoma sensitive detail...
RET rearrange Sunitinib non-small cell lung carcinoma sensitive detail...
Unknown unknown MCLA-128 non-small cell lung carcinoma not applicable detail...
MET over exp Erlotinib + Telisotuzumab vedotin non-small cell lung carcinoma sensitive detail...
Unknown unknown CPI-444 non-small cell lung carcinoma not applicable detail...
Unknown unknown Atezolizumab + CPI-444 non-small cell lung carcinoma not applicable detail...
Unknown unknown TAS-116 non-small cell lung carcinoma not applicable detail...
KRAS mutant Erlotinib + IRX4204 non-small cell lung carcinoma predicted - sensitive detail...
FGFR3-TACC3 Erdafitinib non-small cell lung carcinoma sensitive detail...
RET rearrange CEP-32496 non-small cell lung carcinoma sensitive detail...
BRAF V600E Trametinib + Dabrafenib non-small cell lung carcinoma sensitive detail...
TP53 mutant Pembrolizumab non-small cell lung carcinoma predicted - sensitive detail...
KRAS mutant Pembrolizumab non-small cell lung carcinoma predicted - sensitive detail...
KRAS mutant TP53 mutant Pembrolizumab non-small cell lung carcinoma predicted - sensitive detail...
KRAS G12C AZD4785 non-small cell lung carcinoma sensitive detail...
KRAS Q61H AZD4785 non-small cell lung carcinoma sensitive detail...
KRAS G13D AZD4785 non-small cell lung carcinoma sensitive detail...
KRAS wild-type AZD4785 non-small cell lung carcinoma decreased response detail...
Unknown unknown Cisplatin + Gemcitabine + Metformin non-small cell lung carcinoma not applicable detail...
ROS1 rearrange Ceritinib non-small cell lung carcinoma sensitive detail...
FGFR1 amp GSK3052230 non-small cell lung carcinoma sensitive detail...
Unknown unknown LY2874455 non-small cell lung carcinoma not applicable detail...
BRAF G466V Trametinib non-small cell lung carcinoma sensitive detail...
BRAF G466V NRAS Q61K Trametinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Navitoclax + TAK-901 non-small cell lung carcinoma not applicable detail...
Unknown unknown Barasertib + Navitoclax non-small cell lung carcinoma not applicable detail...
BRAF mutant KO-947 non-small cell lung carcinoma predicted - sensitive detail...
KRAS mutant KO-947 non-small cell lung carcinoma predicted - sensitive detail...
BRAF G466V Trametinib + Dabrafenib non-small cell lung carcinoma sensitive detail...
TP53 negative Seliciclib non-small cell lung carcinoma decreased response detail...
TP53 R175H Seliciclib non-small cell lung carcinoma resistant detail...
TP53 S215G Seliciclib non-small cell lung carcinoma resistant detail...
TP53 Y220C Seliciclib non-small cell lung carcinoma resistant detail...
TP53 P98A Seliciclib non-small cell lung carcinoma decreased response detail...
TP53 A159V Seliciclib non-small cell lung carcinoma decreased response detail...
TP53 Y234C Seliciclib non-small cell lung carcinoma decreased response detail...
TP53 wild-type Seliciclib non-small cell lung carcinoma sensitive detail...
Unknown unknown CCT244747 + Gemcitabine non-small cell lung carcinoma not applicable detail...
Unknown unknown LY2603618 + Pemetrexed non-small cell lung carcinoma no benefit detail...
KRAS mut STK11 inact mut Adavosertib non-small cell lung carcinoma predicted - sensitive detail...
KRAS mut STK11 inact mut MK-1775 + Cisplatin non-small cell lung carcinoma predicted - sensitive detail...
KRAS mut STK11 inact mut MK-1775 + Radiotherapy non-small cell lung carcinoma predicted - sensitive detail...
KRAS mut STK11 loss TP53 loss MK-1775 + Cisplatin non-small cell lung carcinoma predicted - sensitive detail...
KRAS G12D STK11 loss MK-1775 + Cisplatin non-small cell lung carcinoma predicted - sensitive detail...
NRAS mutant KO-947 non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown Bevacizumab-awwb + Carboplatin + Paclitaxel non-small cell lung carcinoma sensitive detail...
STK11 mutant Nivolumab non-small cell lung carcinoma decreased response detail...
BRAF mutant Nivolumab non-small cell lung carcinoma predicted - sensitive detail...
FGFR1 amp NRAS amp BGJ398 non-small cell lung carcinoma resistant detail...
FGFR1 amp NRAS amp Trametinib non-small cell lung carcinoma resistant detail...
FGFR1 amp NRAS amp BGJ398 + Trametinib non-small cell lung carcinoma sensitive detail...
FGFR1 amp NRAS over exp BGJ398 non-small cell lung carcinoma decreased response detail...
FGFR1 amp NRAS over exp BGJ398 + Trametinib non-small cell lung carcinoma sensitive detail...
FGFR1 amp KRAS G12V BGJ398 + Trametinib non-small cell lung carcinoma sensitive detail...
FGFR1 amp KRAS G12V BGJ398 non-small cell lung carcinoma decreased response detail...
FGFR1 amp BGJ398 non-small cell lung carcinoma sensitive detail...
FGFR1 amp BGJ398 + Trametinib non-small cell lung carcinoma sensitive detail...
Unknown unknown Carboplatin + Paclitaxel + Motesanib non-small cell lung carcinoma no benefit detail...
Unknown unknown BJ-1301 non-small cell lung carcinoma not applicable detail...
KRAS G12C GLPG0634 + Selumetinib non-small cell lung carcinoma predicted - sensitive detail...
EML4-ALK Crizotinib + GLPG0634 non-small cell lung carcinoma predicted - sensitive detail...
MET amp MET del exon14 Glesatinib non-small cell lung carcinoma sensitive detail...
KRAS wild-type Selumetinib + Docetaxel non-small cell lung carcinoma no benefit detail...
EML4-ALK ALK F1174V Alectinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK F1174V ALK I1171S Alectinib non-small cell lung carcinoma resistant detail...
Unknown unknown Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel non-small cell lung carcinoma no benefit detail...
ALK rearrange Lorlatinib non-small cell lung carcinoma sensitive detail...
ROS1 rearrange Lorlatinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK I1171T Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK I1171N Alectinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK F1174V Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK L1152R Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK G1269A ALK L1196M Crizotinib non-small cell lung carcinoma resistant detail...
Unknown unknown Cisplatin + Pemetrexed + LY2603618 non-small cell lung carcinoma no benefit detail...
Unknown unknown Cisplatin + PJ34 non-small cell lung carcinoma not applicable detail...
ALK rearrange ALK T1151dup ALK G1269A Crizotinib non-small cell lung carcinoma resistant detail...
ALK amp ALK rearrange Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK G1202R Alectinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK CEP-28122 non-small cell lung carcinoma sensitive detail...
ALK negative CEP-28122 non-small cell lung carcinoma resistant detail...
ALK positive Lorlatinib non-small cell lung carcinoma sensitive detail...
ALK rearrange ALK L1196M Crizotinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK S1206Y Crizotinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK C1156Y Crizotinib non-small cell lung carcinoma resistant detail...
Unknown unknown Pembrolizumab non-small cell lung carcinoma not applicable detail...
KRAS mutant Nivolumab non-small cell lung carcinoma predicted - sensitive detail...
KRAS mutant Atezolizumab non-small cell lung carcinoma predicted - sensitive detail...
SRC positive AC-93253 iodide non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown Durvalumab non-small cell lung carcinoma not applicable detail...
KRAS mutant N/A non-small cell lung carcinoma not applicable detail...
ROS1 rearrange Alectinib non-small cell lung carcinoma no benefit detail...
MET exon 14 Crizotinib non-small cell lung carcinoma sensitive detail...
ERBB2 mutant trastuzumab emtansine non-small cell lung carcinoma sensitive detail...
ALK rearrange Erlotinib non-small cell lung carcinoma no benefit detail...
ALK rearrange Gefitinib non-small cell lung carcinoma no benefit detail...
ALK rearrange Afatinib non-small cell lung carcinoma no benefit detail...
ALK rearrange Osimertinib non-small cell lung carcinoma no benefit detail...
ROS1 rearrange Erlotinib non-small cell lung carcinoma no benefit detail...
ROS1 rearrange Gefitinib non-small cell lung carcinoma no benefit detail...
ROS1 rearrange Afatinib non-small cell lung carcinoma no benefit detail...
ROS1 rearrange Osimertinib non-small cell lung carcinoma no benefit detail...
KRAS mutant Gefitinib non-small cell lung carcinoma no benefit detail...
KRAS mutant Afatinib non-small cell lung carcinoma no benefit detail...
KRAS mutant Osimertinib non-small cell lung carcinoma no benefit detail...
MET amp Merestinib non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 G776_V777insVGC Neratinib non-small cell lung carcinoma predicted - resistant detail...
ERBB2 G776delinsVC Neratinib non-small cell lung carcinoma no benefit detail...
ERBB2 G778_P780dup Neratinib non-small cell lung carcinoma no benefit detail...
ERBB2 L755A Neratinib non-small cell lung carcinoma no benefit detail...
ERBB2 L755P Neratinib non-small cell lung carcinoma no benefit detail...
ERBB2 L755S Neratinib non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 L786V Neratinib non-small cell lung carcinoma no benefit detail...
ERBB2 S310F Neratinib non-small cell lung carcinoma predicted - resistant detail...
ERBB2 V659E Neratinib non-small cell lung carcinoma no benefit detail...
ERBB2 Y772_A775dup Neratinib non-small cell lung carcinoma no benefit detail...
ERBB2 exon 20 ins Neratinib non-small cell lung carcinoma no benefit detail...
MET amp MET del exon14 SCC244 non-small cell lung carcinoma sensitive detail...
MET amp SCC244 non-small cell lung carcinoma sensitive detail...
MET over exp SCC244 non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK F1174V ALK G1202R Ceritinib non-small cell lung carcinoma sensitive detail...
EML4-ALK ALK F1174C Ceritinib non-small cell lung carcinoma resistant detail...
ALK positive Alectinib non-small cell lung carcinoma sensitive detail...
KRAS mut STK11 mut Nivolumab non-small cell lung carcinoma predicted - resistant detail...
KRAS mutant TP53 mutant Nivolumab non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown Panobinostat + Radiotherapy non-small cell lung carcinoma not applicable detail...
Unknown unknown Carboplatin + Paclitaxel + Vorinostat non-small cell lung carcinoma not applicable detail...
Unknown unknown Cisplatin + Etoposide + Panobinostat + Radiotherapy non-small cell lung carcinoma not applicable detail...
Unknown unknown Belinostat + Carboplatin + Paclitaxel non-small cell lung carcinoma not applicable detail...
Unknown unknown Gemcitabine + Milciclib non-small cell lung carcinoma not applicable detail...
BRAF act mut RAF709 non-small cell lung carcinoma sensitive detail...
KRAS act mut RAF709 non-small cell lung carcinoma sensitive detail...
NRAS act mut RAF709 non-small cell lung carcinoma sensitive detail...
Unknown unknown BPI-9016M non-small cell lung carcinoma not applicable detail...
ALK rearrange ALK I1171N ALK L1198F Lorlatinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK I1171N ALK D1203N Lorlatinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK C1156Y ALK L1198F Lorlatinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK G1202R ALK L1196M Lorlatinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK G1202R ALK G1269A ALK L1204V Lorlatinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK E1210K ALK D1203N ALK G1269A Lorlatinib non-small cell lung carcinoma resistant detail...
Unknown unknown Pegilodecakin + Pembrolizumab non-small cell lung carcinoma not applicable detail...
Unknown unknown Nivolumab + Pegilodecakin non-small cell lung carcinoma not applicable detail...
RET fusion LOXO-292 non-small cell lung carcinoma sensitive detail...
MET exon 14 Tepotinib non-small cell lung carcinoma predicted - sensitive detail...
Unknown unknown ALT-803 + Nivolumab non-small cell lung carcinoma not applicable detail...
Unknown unknown Vistusertib + Paclitaxel non-small cell lung carcinoma not applicable detail...
ROS1 fusion ROS1 L2026M ROS1 L1951R Crizotinib non-small cell lung carcinoma resistant detail...
ROS1 fusion ROS1 L2026M ROS1 L1951R Ceritinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK E1210K Crizotinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK E1210K ALK S1206C Brigatinib non-small cell lung carcinoma resistant detail...
EML4-ALK ALK F1174L ALK L1198V Brigatinib non-small cell lung carcinoma resistant detail...
KIT D816G ROS1 fusion Crizotinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK KRAS G12C Crizotinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK KRAS G13D Crizotinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK NOTCH1 D1533A Ceritinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK NOTCH1 D1538A Brigatinib non-small cell lung carcinoma predicted - resistant detail...
ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp Crizotinib non-small cell lung carcinoma predicted - resistant detail...
ROS1 fusion KDR amp KIT amp PDGFRA amp Crizotinib non-small cell lung carcinoma predicted - resistant detail...
ROS1 fusion ERBB2 amp FGFR3 amp RET amp Crizotinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK FGFR1 amp Brigatinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK GNAS amp Crizotinib non-small cell lung carcinoma predicted - resistant detail...
EML4-ALK HRAS amp Crizotinib non-small cell lung carcinoma predicted - resistant detail...
Unknown unknown BIO-11006 non-small cell lung carcinoma not applicable detail...
KRAS mutant HM95573 non-small cell lung carcinoma sensitive detail...
KRAS mutant Selumetinib + SHP099 non-small cell lung carcinoma sensitive detail...
PTPN11 T253M PTPN11 Q257L Selumetinib + SHP099 non-small cell lung carcinoma resistant detail...
MET amp Osimertinib non-small cell lung carcinoma predicted - resistant detail...
KRAS amp MET del exon14 Crizotinib non-small cell lung carcinoma resistant detail...
BRAF G469A Encorafenib + Trametinib non-small cell lung carcinoma sensitive detail...
KRAS amp MET del exon14 Crizotinib + Trametinib non-small cell lung carcinoma predicted - resistant detail...
KRAS amp MET del exon14 Copanlisib + Crizotinib non-small cell lung carcinoma sensitive detail...
KRAS amp MET del exon14 Copanlisib non-small cell lung carcinoma predicted - sensitive detail...
KRAS amp MET del exon14 Linsitinib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Crizotinib + Lapatinib + Linsitinib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Crizotinib + Lapatinib non-small cell lung carcinoma no benefit detail...
BRAF G469A Dabrafenib non-small cell lung carcinoma sensitive detail...
KRAS amp MET del exon14 Alpelisib + Crizotinib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Crizotinib + Linsitinib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Crizotinib + Gefitinib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Lapatinib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Alpelisib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Gefitinib non-small cell lung carcinoma no benefit detail...
KRAS amp MET del exon14 Trametinib non-small cell lung carcinoma no benefit detail...
ERBB2 Y772_A775dup Afatinib non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Dacomitinib non-small cell lung carcinoma no benefit detail...
ERBB2 Y772_A775dup Erlotinib non-small cell lung carcinoma no benefit detail...
ERBB2 Y772_A775dup Poziotinib non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 G776delinsVC Dacomitinib non-small cell lung carcinoma no benefit detail...
ERBB2 G776delinsVC Erlotinib non-small cell lung carcinoma no benefit detail...
ERBB2 G776delinsVC Lapatinib non-small cell lung carcinoma no benefit detail...
ERBB2 G776delinsVC Poziotinib non-small cell lung carcinoma predicted - sensitive detail...
ERBB2 G778_P780dup Afatinib non-small cell lung carcinoma predicted - sensitive detail...
ALK rearrange ALK G1202R Brigatinib non-small cell lung carcinoma predicted - resistant detail...
ALK rearrange ALK I1171N Brigatinib non-small cell lung carcinoma predicted - sensitive detail...
ALK rearrange ALK I1171T Brigatinib non-small cell lung carcinoma predicted - resistant detail...
ALK rearrange ALK V1180L Brigatinib non-small cell lung carcinoma predicted - sensitive detail...
ALK rearrange ALK V1180L Alectinib non-small cell lung carcinoma resistant detail...
ALK rearrange ALK I1171T Alectinib non-small cell lung carcinoma predicted - resistant detail...
ALK rearrange ALK V1180L ALK L1196M ALK G1202R Brigatinib non-small cell lung carcinoma predicted - resistant detail...
ALK rearrange ALK D1203N Brigatinib non-small cell lung carcinoma predicted - resistant detail...
ALK rearrange ALK I1171N MET amp Brigatinib non-small cell lung carcinoma predicted - resistant detail...
BRAF D594N RMC-4550 non-small cell lung carcinoma predicted - sensitive detail...
BRAF N581D RMC-4550 non-small cell lung carcinoma predicted - sensitive detail...
KRAS G12C RMC-4550 non-small cell lung carcinoma sensitive detail...
Unknown unknown Abemaciclib + Pemetrexed non-small cell lung carcinoma not applicable detail...
Unknown unknown Abemaciclib + Gemcitabine non-small cell lung carcinoma not applicable detail...
Unknown unknown Abemaciclib + Ramucirumab non-small cell lung carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00150657 Phase II Gemcitabine + Bevacizumab + Carboplatin Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer Unknown status
NCT00254319 Phase II Carboplatin Bevacizumab + Pemetrexed Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Unknown status
NCT00547105 Phase II Erlotinib Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer Completed
NCT00569296 EGFRBi-armed autologous activated T cells Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer Terminated
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Recruiting
NCT00828009 Phase II Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT00932451 Phase II Crizotinib An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed
NCT00950365 Phase II Erlotinib + Pemetrexed Pemetrexed Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status
NCT00975767 Phase Ib/II Docetaxel + Glesatinib Glesatinib + Erlotinib A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer Terminated
NCT00978250 Phase II FdCyd + THU A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Active, not recruiting
NCT00979212 Phase II Panitumumab Paclitaxel + Carboplatin Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) Active, not recruiting
NCT00997334 Phase II Erlotinib Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC Completed
NCT01005797 Phase I Panobinostat + Sorafenib Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Completed
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Active, not recruiting
NCT01059552 Phase I Vorinostat Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT01061788 Phase I AMG479 + Everolimus + Panitumumab A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer Active, not recruiting
NCT01107626 Phase III Pemetrexed Bevacizumab Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT01177397 Phase Ib/II CC-223 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01179269 Phase II Pazopanib + Paclitaxel Stage IIIB/IV Non-Small Cell Lung Cancer Withdrawn
NCT01210378 Phase II Nitroglycerin Nitroglycerin in Non-small Cell Lung Cancer Terminated
NCT01233687 Phase Ib/II AMG102 Erlotinib AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer Completed
NCT01248247 Phase I Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study Active, not recruiting
NCT01263782 Phase II Bevacizumab Carboplatin + Pemetrexed Cixutumumab BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer Completed
NCT01288430 Phase I DS-2248 A Study of DS-2248, in Subjects With Advanced Solid Tumors Terminated
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting
NCT01307267 Phase I Utomilumab + Rituximab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Active, not recruiting
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Active, not recruiting
NCT01336634 Phase II Dabrafenib Trametinib + Dabrafenib Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Active, not recruiting
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed
NCT01344824 Phase II Bevacizumab Erlotinib Carboplatin Pemetrexed Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers Completed
NCT01351415 Phase III Bevacizumab A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer Completed
NCT01383148 Phase Ib/II MVA-MUC1-IL2 vaccine Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated
NCT01386385 Phase Ib/II Paclitaxel + Carboplatin Carboplatin + Etoposide + Veliparib Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Active, not recruiting
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Active, not recruiting
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Active, not recruiting
NCT01455389 Phase Ib/II DOTAP:chol-Fus1 Erlotinib Diphenhydramine Dexamethasone FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer Active, not recruiting
NCT01456325 Phase III Erlotinib Onartuzumab A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) Completed
NCT01465802 Phase II Dacomitinib Alclometasone Doxycycline Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed
NCT01487265 Phase II BKM120 + Erlotinib Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib Active, not recruiting
NCT01493843 Phase II Carboplatin Pictilisib Bevacizumab Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer Completed
NCT01514864 Phase II Dasatinib Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Terminated
NCT01526928 Phase Ib/II Rociletinib Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients Active, not recruiting
NCT01532089 Phase II Bevacizumab Erlotinib Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations Active, not recruiting
NCT01537744 Phase I Azacitidine + Romidepsin A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer Completed
NCT01545947 Phase I Azacitidine + CC-223 Erlotinib + CC-223 Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer Completed
NCT01553942 Phase II Afatinib Cisplatin Pemetrexed Afatinib With CT and RT for EGFR-Mutant NSCLC Recruiting
NCT01573702 Phase II Erlotinib Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Active, not recruiting
NCT01574729 Phase II rAD-p53 Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma Unknown status
NCT01578551 Phase II Metformin Paclitaxel + Carboplatin Bevacizumab A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Terminated
NCT01587703 Phase I GSK525762 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Active, not recruiting
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT01620190 Phase II nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed
NCT01628471 Phase Ib/II Genistein + Decitabine MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer Completed
NCT01630733 Phase III Docetaxel Custirsen + Docetaxel A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Unknown status
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes Recruiting
NCT01642251 Phase Ib/II Cisplatin + Etoposide Veliparib Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Completed
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Recruiting
NCT01646125 Docetaxel Luminespib Pemetrexed An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Terminated
NCT01647711 Phase I Afatinib A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations Completed
NCT01649284 Phase I Afatinib Afatinib Expanded Access Program Approved for marketing
NCT01649947 Phase II Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine Paclitaxel + Carboplatin + Hydroxychloroquine Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II Completed
NCT01653470 Phase I Carboplatin FOLFIRI BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed
NCT01664754 Phase I Pemetrexed Carboplatin Exemestane Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer Active, not recruiting
NCT01676714 Phase II Dovitinib Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Completed
NCT01700400 Phase I Carboplatin Everolimus Bevacizumab Pemetrexed Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Completed
NCT01708993 Phase II Docetaxel Pemetrexed Reolysin + Pemetrexed Reolysin + Docetaxel Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Completed
NCT01712217 Phase Ib/II Crizotinib AT13387 A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Completed
NCT01717482 Phase II Metformin Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer Active, not recruiting
NCT01723800 Phase I BKM120 + Pemetrexed + Carboplatin PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer Completed
NCT01725165 Phase II Oligometastatic Disease Active, not recruiting
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01746251 Phase II Afatinib Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation Active, not recruiting
NCT01750281 Phase II Docetaxel Selumetinib + Docetaxel Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Active, not recruiting
NCT01752400 Phase II Luminespib AUY922 for Advanced ALK-positive NSCLC Completed
NCT01769391 Phase II Necitumumab Paclitaxel + Carboplatin A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer Completed
NCT01772797 Phase I Ceritinib Luminespib Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Completed
NCT01783197 Phase I Selumetinib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Active, not recruiting
NCT01784640 Phase I Luminespib + Pemetrexed Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Active, not recruiting
NCT01788566 Phase II Necitumumab + Gemcitabine + Cisplatin A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer Completed
NCT01798485 Phase III Ganetespib Docetaxel A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated
NCT01801111 Phase II Erlotinib Alectinib A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment Completed
NCT01802632 Phase Ib/II Osimertinib AZD9291 First Time In Patients Ascending Dose Study Active, not recruiting
NCT01803282 Phase I GS-5745 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed FOLFIRI Nab-paclitaxel + Gemcitabine Paclitaxel + Carboplatin Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Active, not recruiting
NCT01813734 Phase II Ponatinib Ponatinib in Advanced NSCLC w/ RET Translocations Completed
NCT01820754 Phase II Cisplatin Ipilimumab Carboplatin Paclitaxel Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Completed
NCT01822496 Phase II Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated
NCT01828112 Phase III Docetaxel Pemetrexed Ceritinib LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting
NCT01829217 Phase II Sunitinib Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed
NCT01831089 Phase I Lurbinectedin + Paclitaxel + Bevacizumab Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01833143 Phase II Bortezomib Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D Active, not recruiting
NCT01837329 Phase I Tetrathiomolybdate Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer Recruiting
NCT01839955 Phase Ib/II Erlotinib + Quinacrine Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer Completed
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated
NCT01854034 Phase II Luminespib Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Completed
NCT01857271 Phase II Erlotinib Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated
NCT01858389 Phase II Dacomitinib A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer Completed
NCT01859026 Phase I MEK162 + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Recruiting
NCT01866410 Phase II Cabozantinib + Erlotinib Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer Completed
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed GSK3052230 Paclitaxel + Carboplatin Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed
NCT01871805 Phase Ib/II Alectinib A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Completed
NCT01884285 Phase I AZD8186 AZD8186 First Time In Patient Ascending Dose Study Recruiting
NCT01887886 Phase III Onartuzumab + Erlotinib A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation Completed
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed
NCT01900652 Phase II Emibetuzumab + Erlotinib Emibetuzumab A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants Completed
NCT01903993 Phase II Atezolizumab A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" Completed
NCT01911325 Phase Ib/II Buparlisib Docetaxel Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Terminated
NCT01911507 Phase I INCB028060 + Erlotinib INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer Recruiting
NCT01912625 Phase I Carboplatin + Paclitaxel + Trametinib Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT01920061 Phase I PF-05212384 + Dacomitinib PF-05212384 + Cisplatin Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents Recruiting
NCT01928160 Phase II Erlotinib + Pemetrexed Pemetrexed Carboplatin Erlotinib + Carboplatin Cisplatin Erlotinib + Cisplatin Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Withdrawn
NCT01928576 Phase II Nivolumab Entinostat Azacitidine Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. Recruiting
NCT01933932 Phase III Selumetinib + Docetaxel Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC Active, not recruiting
NCT01935947 Phase II Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Terminated
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Active, not recruiting
NCT01947608 Phase I Ceritinib Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC Available
NCT01951690 Phase II Defactinib Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Completed
NCT01957007 Phase I Docetaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC Completed
NCT01966003 Phase III Bevacizumab Bevacizumab-awwb Paclitaxel + Carboplatin Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer Completed
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01967095 Phase I Erlotinib Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01970865 Phase Ib/II Lorlatinib Crizotinib A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations Active, not recruiting
NCT01974258 Phase I Onartuzumab + Vemurafenib Onartuzumab + Cobimetinib Onartuzumab + Cobimetinib + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01993810 Phase III Carboplatin + Pemetrexed Durvalumab Cisplatin + Etoposide Paclitaxel + Carboplatin Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Recruiting
NCT01998126 Phase I Ipilimumab + Erlotinib Ipilimumab + Crizotinib Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts Completed
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed
NCT01999985 Phase I Dasatinib + Afatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02000947 Phase Ib/II Durvalumab + Tremelimumab A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer Active, not recruiting
NCT02004106 Phase I RO6895882 A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed
NCT02008227 Phase III Docetaxel Atezolizumab A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK Completed
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02013219 Phase I Alectinib + Atezolizumab Atezolizumab + Erlotinib A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer Active, not recruiting
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab Cetuximab + CDX-3379 CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02019979 Phase II Metformin Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO) Terminated
NCT02022982 Phase Ib/II PD-0325901 + Palbociclib PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Active, not recruiting
NCT02031458 Phase II Atezolizumab A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH Completed
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn
NCT02039674 Phase Ib/II Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pemetrexed Ipilimumab + Pembrolizumab Erlotinib + Pembrolizumab Gefitinib + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) Active, not recruiting
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Active, not recruiting
NCT02043665 Phase I coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Active, not recruiting
NCT02044601 Phase Ib/II Onartuzumab + Paclitaxel + Carboplatin Onartuzumab + Erlotinib + Paclitaxel + Carboplatin Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) Withdrawn
NCT02045446 Phase II Bevacizumab + Erlotinib Gemcitabine + Docetaxel Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02047344 Phase II Antroquinonol Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC Recruiting
NCT02066636 Phase III Nivolumab A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) Active, not recruiting
NCT02075840 Phase III Alectinib Crizotinib ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Active, not recruiting
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Active, not recruiting
NCT02080078 Phase I Erlotinib + Theophylline A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Unknown status
NCT02085070 Phase II Pembrolizumab MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Active, not recruiting
NCT02087176 Phase II Adavosertib Pegfilgrastim A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer Terminated
NCT02087241 Phase II Adavosertib Carboplatin + Pemetrexed Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer Terminated
NCT02087423 Phase II Durvalumab A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) Active, not recruiting
NCT02088112 Phase I Gefitinib Durvalumab MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC) Active, not recruiting
NCT02091999 Phase I Enfortumab vedotin A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Recruiting
NCT02094573 Phase II Brigatinib A Phase 2, Multicenter, Randomized Study of AP26113 Active, not recruiting
NCT02106546 Phase III Veliparib Paclitaxel + Carboplatin Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT02108964 Phase Ib/II Nazartinib A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies Active, not recruiting
NCT02109016 Phase II Lucitanib A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer Terminated
NCT02113813 Phase I Naquotinib A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Active, not recruiting
NCT02115464 Phase II Metformin Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy Recruiting
NCT02117024 Phase II HS-110 + Cyclophosphamide Pemetrexed Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Active, not recruiting
NCT02119650 Phase II Ruxolitinib + Cisplatin + Pemetrexed Cisplatin + Pemetrexed Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Terminated
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Active, not recruiting
NCT02125461 Phase III Durvalumab A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) Active, not recruiting
NCT02132598 Phase II Cabozantinib Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases Recruiting
NCT02134015 Phase III Erlotinib Patritumab + Erlotinib Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Terminated
NCT02134886 Phase I Erlotinib Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection Terminated
NCT02134912 Phase II Crizotinib + Pemetrexed Pemetrexed S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Terminated
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Active, not recruiting
NCT02143466 Phase I Osimertinib + Savolitinib Osimertinib + Selumetinib AZD9291 + MEDI4736 AZD9291 in Combination With Ascending Doses of Novel Therapeutics Recruiting
NCT02147990 Phase II Rociletinib Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI Active, not recruiting
NCT02151981 Phase III Osimertinib AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT02152631 Phase III Erlotinib Abemaciclib A Study of LY2835219 in Participants With Previously Treated Lung Cancer Active, not recruiting
NCT02154490 Phase II Docetaxel Palbociclib Durvalumab AZD4547 Taselisib Erlotinib AMG102 Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer Recruiting
NCT02157792 Phase I Cisplatin Etoposide VX-970 Gemcitabine An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy Recruiting
NCT02157883 Phase I Itraconazole Osimertinib Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Active, not recruiting
NCT02163733 Phase I Osimertinib Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Active, not recruiting
NCT02168777 Phase Ib/II Regorafenib + Refametinib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated
NCT02174172 Phase I Atezolizumab + Bevacizumab +Peg-interferon alfa-2a Atezolizumab + Interferon alfa-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02178722 Phase Ib/II Pembrolizumab Epacadostat A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) Active, not recruiting
NCT02179671 Phase II Selumetinib + Docetaxel Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
NCT02186301 Phase II Rociletinib Erlotinib TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy Terminated
NCT02186847 Phase II Metformin Paclitaxel + Carboplatin Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Recruiting
NCT02192541 Phase I Ganetespib + Aflibercept Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Active, not recruiting
NCT02193282 Phase III Erlotinib Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Recruiting
NCT02194738 Phase I Nivolumab Crizotinib Erlotinib Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting
NCT02197234 Phase I Osimertinib + Simvastatin Osimertinib Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC Active, not recruiting
NCT02197247 Phase I Osimertinib + Rifampin Osimertinib Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC Active, not recruiting
NCT02201992 Phase III Crizotinib Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Recruiting
NCT02206763 Phase I Erlotinib + Momelotinib Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated
NCT02220894 Phase III Pemetrexed Paclitaxel + Carboplatin Pembrolizumab Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Active, not recruiting
NCT02221739 Phase II Ipilimumab Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) Completed
NCT02222922 Phase I Fluconazole PF-06647020 A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Recruiting
NCT02225405 Phase I Cisplatin + Docetaxel + Nintedanib Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC) Active, not recruiting
NCT02228369 Phase I Osimertinib AZD3759 Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT02250326 Phase II Abraxane + Azacitidine nab-paclitaxel Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer Active, not recruiting
NCT02257619 Phase II Docetaxel Itacitinib Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Terminated
NCT02258607 Phase I Momelotinib Momelotinib + Trametinib Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase Terminated
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed
NCT02259582 Phase II Carboplatin + Pemetrexed Demcizumab A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer Completed
NCT02259621 Phase II Nivolumab Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC Recruiting
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + MEDI4736 AZD6738 + Olaparib Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting
NCT02264990 Phase III Pemetrexed Carboplatin Paclitaxel Veliparib Cisplatin Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers Active, not recruiting
NCT02271139 Phase III Alectinib Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib No longer available
NCT02271906 Phase II Afatinib The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting Terminated
NCT02272413 Phase III Paclitaxel + Carboplatin Bevacizumab Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer Completed
NCT02273375 Phase III Durvalumab Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC Recruiting
NCT02277457 Phase I Crizotinib Erlotinib Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations Withdrawn
NCT02279433 Phase I DS6051b A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Active, not recruiting
NCT02283320 Phase II Docetaxel A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Completed
NCT02289833 Phase II trastuzumab emtansine A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
NCT02292550 Phase Ib/II Ceritinib + LEE011 Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. Completed
NCT02296125 Phase III Erlotinib Osimertinib Gefitinib AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting
NCT02298153 Phase I Atezolizumab + Epacadostat A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Terminated
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Recruiting
NCT02299505 Phase I Ceritinib Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Unknown status
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed
NCT02309892 Phase I L-DOS47 + Carboplatin + Pemetrexed A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC Recruiting
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02314364 Phase II A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC Recruiting
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02316002 Phase II Pembrolizumab Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT02317016 Phase I Osimertinib Rosuvastatin Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer Completed
NCT02318368 Phase II Erlotinib Ficlatuzumab + Erlotinib A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label Terminated
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Active, not recruiting
NCT02321293 Phase I Erlotinib + Gefitinib A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC Unknown status
NCT02321501 Phase I Ceritinib + Everolimus Ceritinib Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression Recruiting
NCT02321540 Phase Ib/II Ibrutinib A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer Active, not recruiting
NCT02322281 Phase III Pemetrexed Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated
NCT02323126 Phase II Nazartinib + Nivolumab INC280 + Nivolumab Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer Recruiting
NCT02327078 Phase Ib/II INCB024360 + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed
NCT02335944 Phase Ib/II Capmatinib + Nazartinib Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation. Recruiting
NCT02336451 Phase II Ceritinib A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges Recruiting
NCT02337530 Phase II Selumetinib Cisplatin + Pemetrexed Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT02342353 Phase Ib/II Erlotinib + Pacritinib Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) Terminated
NCT02343952 Phase II Pembrolizumab Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Active, not recruiting
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02349633 Phase I PF-06747775 Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) Active, not recruiting
NCT02350764 Phase II Nivolumab Evaluate the Mediators of Sensitivity and Resistance to Nivolumab in Patients With Advanced NSCLCs Recruiting
NCT02352948 Phase III Durvalumab Erlotinib + Gemcitabine + Vinorelbine Durvalumab + Tremelimumab Tremelimumab A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Active, not recruiting
NCT02355431 Phase II Erlotinib Itacitinib INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations Withdrawn
NCT02357836 Phase I Itraconazole Neoadjuvant Itraconazole in Non-small Cell Lung Cancer Recruiting
NCT02364609 Phase I Afatinib + Pembrolizumab Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Active, not recruiting
NCT02364999 Phase III Bevacizumab + Carboplatin + Paclitaxel A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC Completed
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated
NCT02366143 Phase III Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Nab-paclitaxel + Carboplatin + Bevacizumab Atezolizumab + Carboplatin + Paclitaxel TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Active, not recruiting
NCT02367781 Phase III Atezolizumab Carboplatin + nab-paclitaxel A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT02367794 Phase III Carboplatin nab-paclitaxel Paclitaxel Atezolizumab A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Active, not recruiting
NCT02382406 Phase Ib/II Pembrolizumab Carboplatin + nab-paclitaxel Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC Recruiting
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Active, not recruiting
NCT02387216 Phase II Seribantumab Pemetrexed Docetaxel A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Recruiting
NCT02391480 Phase I ABBV-075 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Active, not recruiting
NCT02392507 Phase II Carboplatin + nab-paclitaxel + Necitumumab A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC Active, not recruiting
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies Recruiting
NCT02393625 Phase I Ceritinib + Nivolumab Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Recruiting
NCT02395172 Phase III Avelumab Docetaxel Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Active, not recruiting
NCT02400814 Phase I Atezolizumab MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer Recruiting
NCT02403193 Phase Ib/II PBF-509 + PDR001 PBF-509 Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) Recruiting
NCT02403271 Phase Ib/II Ibrutinib + MEDI4736 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed
NCT02404441 Phase Ib/II PDR001 Phase I/II Study of PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Recruiting
NCT02409342 Phase III Atezolizumab Carboplatin Pemetrexed Cisplatin A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02409355 Phase III Carboplatin Cisplatin Gemcitabine Atezolizumab A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Terminated
NCT02411448 Phase III Erlotinib Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC Active, not recruiting
NCT02412371 Phase II Veliparib Paclitaxel + Carboplatin A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer Active, not recruiting
NCT02414139 Phase II Capmatinib Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy Recruiting
NCT02422381 Phase Ib/II Gemcitabine Pembrolizumab MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02422589 Phase I Warfarin Midazolam Ceritinib A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors Completed
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Active, not recruiting
NCT02424617 Phase Ib/II BGB-324 + Erlotinib A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Recruiting
NCT02432963 Phase I MVAp53 Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02435121 Phase II SAR125844 A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Completed
NCT02437136 Phase Ib/II Entinostat + Pembrolizumab Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma Active, not recruiting
NCT02438722 Phase II Afatinib Cetuximab S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Active, not recruiting
NCT02439450 Phase I HS-110 Nivolumab A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Recruiting
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Active, not recruiting
NCT02444741 Phase Ib/II Pembrolizumab MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02448251 Phase Ib/II Avitinib maleate Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer Recruiting
NCT02448303 Phase II Acalabrutinib Pembrolizumab Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer Unknown status
NCT02450539 Phase II Abemaciclib Docetaxel A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Active, not recruiting
NCT02451852 Phase I Osimertinib AZD9291 US Expanded Access Program No longer available
NCT02451865 Phase I Binimetinib + Docetaxel Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer Withdrawn
NCT02451930 Phase I Necitumumab Pembrolizumab A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Active, not recruiting
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Completed
NCT02453282 Phase III Durvalumab Gemcitabine + Cisplatin Paclitaxel + Carboplatin Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Active, not recruiting
NCT02454842 Phase II TH-4000 Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC Terminated
NCT02454933 Phase III Osimertinib Durvalumab Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours Active, not recruiting
NCT02460224 Phase Ib/II LAG525 PDR001 Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02460367 Phase Ib/II Docetaxel + Indoximod Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer Unknown status
NCT02463994 Phase I Atezolizumab A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC Completed
NCT02468661 Phase Ib/II Capmatinib Erlotinib Cisplatin + Pemetrexed Carboplatin + Pemetrexed A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Recruiting
NCT02469701 Phase II Nivolumab BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease Terminated
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02474355 Phase III Osimertinib Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Active, not recruiting
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Active, not recruiting
NCT02475382 Expanded access Nivolumab Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) No longer available
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02485652 Phase II Olmutinib Phase II Trial of HM61713 (BI 1482694) for the Treatment of >2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NSCLC) Active, not recruiting
NCT02486718 Phase III Atezolizumab Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer Active, not recruiting
NCT02487095 Phase Ib/II VX-970 Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Recruiting
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Recruiting
NCT02495636 Phase II Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer Withdrawn
NCT02496663 Phase I Necitumumab Osimertinib EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Recruiting
NCT02498613 Phase II Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Recruiting
NCT02503358 Phase I Selumetinib nab-paclitaxel Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Recruiting
NCT02503722 Phase I AZD9291 + MLN0128 TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor Recruiting
NCT02504372 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) Recruiting
NCT02504489 Phase III Docetaxel Docetaxel + Plinabulin Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion Recruiting
NCT02509507 Phase I Pembrolizumab + talimogene laherparepvec talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02511106 Phase III Osimertinib AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy Recruiting
NCT02511184 Phase I Crizotinib Pembrolizumab Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients Terminated
NCT02514174 FDA approved Afatinib Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Active, not recruiting
NCT02516813 Phase I MSC2490484A Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Recruiting
NCT02520778 Phase I Navitoclax + Osimertinib EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Recruiting
NCT02521051 Phase Ib/II Bevacizumab Alectinib Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Recruiting
NCT02523469 Phase Ib/II ALT-803 + Nivolumab ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting
NCT02525757 Phase II Atezolizumab Paclitaxel + Carboplatin MPDL3280A With Chemoradiation for Lung Cancer Active, not recruiting
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Active, not recruiting
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT02535338 Phase Ib/II Erlotinib + Onalespib Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer Active, not recruiting
NCT02537561 Phase I Talazoparib Gemcitabine + Cisplatin Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors Withdrawn
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02542293 Phase III Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab + Tremelimumab Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). Active, not recruiting
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02544633 Phase II Glesatinib Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET Completed
NCT02546986 Phase II Azacitidine Pembrolizumab Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting
NCT02547675 Phase I Rociletinib Rociletinib (CO-1686) USA Expanded Access Program No longer available
NCT02554812 Phase I Avelumab + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting
NCT02563548 Phase I PEGPH20 + Pembrolizumab Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab Active, not recruiting
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2) Recruiting
NCT02572687 Phase I MEDI4736 + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Active, not recruiting
NCT02573259 Phase I PF-06801591 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Recruiting
NCT02574078 Phase I nab-paclitaxel Crizotinib Bevacizumab + Pemetrexed Paclitaxel Docetaxel Nivolumab Pemetrexed Gemcitabine Erlotinib Carboplatin A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370) Active, not recruiting
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02576431 Phase II Larotrectinib Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Recruiting
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Carboplatin Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) Active, not recruiting
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting
NCT02578680 Phase III Carboplatin Pembrolizumab Pemetrexed Cisplatin Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Active, not recruiting
NCT02580708 Phase Ib/II Trametinib Rociletinib A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Terminated
NCT02581787 Phase Ib/II fresolimumab SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Recruiting
NCT02581943 Phase II Paclitaxel Pembrolizumab Carboplatin Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Recruiting
NCT02584634 Phase I Crizotinib Avelumab Lorlatinib Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Active, not recruiting
NCT02588261 Phase III Naquotinib Gefitinib Erlotinib A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations Terminated
NCT02589522 Phase I VX-970 VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Recruiting
NCT02591615 Phase II Pembrolizumab Paclitaxel + Carboplatin Carboplatin + Pemetrexed Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Recruiting
NCT02592577 Phase I MAGE A10c796T for Advanced NSCLC Recruiting
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting
NCT02595944 Phase III Nivolumab Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL) Recruiting
NCT02599454 Phase I Atezolizumab Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Recruiting
NCT02605746 Phase I Ceritinib Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis Unknown status
NCT02608268 Phase Ib/II PDR001 MBG453 Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Recruiting
NCT02609776 Phase I JNJ-61186372 A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer Recruiting
NCT02616393 Phase II XL647 Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases Completed
NCT02621398 Phase I Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer Recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Active, not recruiting
NCT02630186 Phase Ib/II Atezolizumab + Rociletinib A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC Completed
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02635061 Phase I ACY-241 + Ipilimumab + Nivolumab Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer Recruiting
NCT02637531 Phase I Pembrolizumab IPI-549 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Recruiting
NCT02638090 Phase Ib/II Pembrolizumab Vorinostat Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Recruiting
NCT02639091 Phase I Anetumab ravtansine + Cisplatin + Pemetrexed Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Active, not recruiting
NCT02639234 Phase II FANG vaccine + Nivolumab Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer Withdrawn
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Recruiting
NCT02642042 Phase II Docetaxel + Trametinib Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer Active, not recruiting
NCT02642939 Phase II Mifepristone Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting
NCT02646748 Phase I INCB050465 Pembrolizumab Itacitinib Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Recruiting
NCT02650635 Phase I Cyclophosphamide + Pegfilgrastim + VTX-2337 TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02654587 Phase III OSE 2101 Docetaxel + Pemetrexed Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1) Recruiting
NCT02655822 Phase I Atezolizumab CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02657434 Phase III Cisplatin Atezolizumab Carboplatin Pemetrexed A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer Recruiting
NCT02658097 Phase II Pembrolizumab A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Recruiting
NCT02659059 Phase II Nivolumab + Ipilimumab Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) Active, not recruiting
NCT02664181 Phase II Nivolumab Decitabine + Nivolumab + Tetrahydrouridine Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) Active, not recruiting
NCT02666105 Phase II Exemestane Exemestane in Post-Menopausal Women With NSCLC Recruiting
NCT02669914 Phase II Durvalumab MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Terminated
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02681549 Phase II Bevacizumab + Pembrolizumab Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Recruiting
NCT02684461 Phase II Pembrolizumab Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel Recruiting
NCT02695290 Phase III Afatinib Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) Terminated
NCT02696993 Phase Ib/II Nivolumab Ipilimumab Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer Recruiting
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Recruiting
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated
NCT02706626 Phase II Brigatinib Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors Recruiting
NCT02710396 Phase II Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Recruiting
NCT02713529 Phase Ib/II AMG820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Active, not recruiting
NCT02713828 Phase Ib/II Glembatumumab vedotin Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Terminated
NCT02713867 Phase III Nivolumab A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) Active, not recruiting
NCT02715284 Phase I TSR-042 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting
NCT02716038 Phase II Atezolizumab + Carboplatin + nab-Paclitaxel Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Recruiting
NCT02716116 Phase Ib/II AP32788 A Trial of AP32788 in Non-Small Cell Lung Cancer Recruiting
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Recruiting
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT02730247 Phase II Abraxane + Ramucirumab Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02733250 Phase Ib/II nab-paclitaxel + Pembrolizumab Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) Active, not recruiting
NCT02737501 Phase III Brigatinib Crizotinib ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Active, not recruiting
NCT02740985 Phase I AZD4635 AZD4635 + MEDI4736 A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies Recruiting
NCT02750215 Phase II Capmatinib A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting
NCT02750514 Phase II Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab BMS-986205 + Nivolumab An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) Recruiting
NCT02767804 Phase III Crizotinib Ensartinib eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Active, not recruiting
NCT02768558 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Nivolumab Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC Terminated
NCT02770014 Phase II Erlotinib Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Active, not recruiting
NCT02775435 Phase III Carboplatin + nab-paclitaxel Pembrolizumab Paclitaxel + Carboplatin A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Active, not recruiting
NCT02779751 Phase II Abemaciclib + Pembrolizumab A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Recruiting
NCT02784158 Phase I Brigatinib An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer No longer available
NCT02789345 Phase I Osimertinib + Ramucirumab Necitumumab + Osimertinib A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Active, not recruiting
NCT02795156 Phase II Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02803203 Phase Ib/II Bevacizumab + Osimertinib Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers Recruiting
NCT02805660 Phase Ib/II MEDI4736 + Mocetinostat Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC Active, not recruiting
NCT02810457 Phase III Bevacizumab + Carboplatin + Paclitaxel Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA) Active, not recruiting
NCT02812667 Phase I Nivolumab + Plinabulin Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02818920 Phase II Pembrolizumab Neoadjuvant Pembrolizumab Active, not recruiting
NCT02823990 Phase II MVA-MUC1-IL2 vaccine + Nivolumab TG4010 and Nivolumab in Patients With Lung Cancer Active, not recruiting
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Active, not recruiting
NCT02826161 Phase III Napabucasin + Paclitaxel Paclitaxel A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) Terminated
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Recruiting
NCT02831491 Phase II Ramucirumab + Docetaxel A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer Withdrawn
NCT02831933 Phase II AdV-tk + Nivolumab Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN) Recruiting
NCT02834247 Phase I Nivolumab + TAK-659 A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Completed
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed
NCT02840994 Phase Ib/II CV301 + Nivolumab Nivolumab A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer Active, not recruiting
NCT02846792 Phase Ib/II Nivolumab + Plinabulin Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer Recruiting
NCT02848651 Phase II Atezolizumab A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] Active, not recruiting
NCT02855125 Phase II TS-1 TAS-114 + TS-1 A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Completed
NCT02857270 Phase I LY3214996 LY3214996 + nab-paclitaxel + Gemcitabine LY3214996 + Midazolam LY3214996 + Abemaciclib A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed
NCT02864251 Phase III Nivolumab Nivolumab + Ipilimumab Carboplatin + Cisplatin + Pemetrexed A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722) Recruiting
NCT02869789 Phase III Nivolumab + Ipilimumab A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Recruiting
NCT02879617 Phase II Durvalumab A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Recruiting
NCT02879760 Phase Ib/II Pembrolizumab + Ad-MAGEA3 + MG1-MAGEA3 Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients Recruiting
NCT02879994 Phase II Pembrolizumab Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Recruiting
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Recruiting
NCT02890069 Phase I PDR001 + LCL161 PDR001 + Everolimus PDR001 + Panobinostat A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Recruiting
NCT02897375 Phase I Cisplatin + Palbociclib Carboplatin + Palbociclib Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Recruiting
NCT02897765 Phase I Nivolumab NEO-PV-01 + poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Active, not recruiting
NCT02898116 Phase Ib/II MEDI4736 + X-396 Ensartinib A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer Completed
NCT02900664 Phase I PDR001 + Nazartinib PDR001 + CJM112 PDR001 + Trametinib PDR001 + Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Recruiting
NCT02904954 Phase II Durvalumab Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer Recruiting
NCT02917993 Phase Ib/II INCB039110 + Osimertinib An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Recruiting
NCT02919449 Phase I MV-NIS + Atezolizumab Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer Terminated
NCT02920450 Phase Ib/II Gedatolisib + Paclitaxel + Carboplatin Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC Active, not recruiting
NCT02920996 Phase II Merestinib Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Recruiting
NCT02922764 Phase I RGX-104 Nivolumab + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02922777 Phase I BGB-324 + Docetaxel Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. Recruiting
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02926768 Phase Ib/II CK-101 Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Recruiting
NCT02927301 Phase II Atezolizumab A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02927340 Phase II Lorlatinib A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions Recruiting
NCT02936102 Phase I FAZ053 FAZ053 + PDR001 A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02941601 Phase II Necitumumab + Gemcitabine + Carboplatin A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Withdrawn
NCT02942095 Phase I Erlotinib + Ixazomib Phase I Study of Ixazomib and Erlotinib in Solid Tumors Recruiting
NCT02944396 Phase II Carboplatin + Paclitaxel + Pemetrexed + Veliparib Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02947165 Phase I NIS793 + PDR001 NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02947386 Phase Ib/II Nimotuzumab + Nivolumab Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer Recruiting
NCT02949843 Phase II Nivolumab + Pembrolizumab Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Recruiting
NCT02950038 Phase II Ibrutinib + Nivolumab Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Withdrawn
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Active, not recruiting
NCT02952989 Phase I SGN-2FF A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Recruiting
NCT02954523 Phase Ib/II Dasatinib + Osimertinib Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Active, not recruiting
NCT02954991 Phase II MGCD516 + Nivolumab Mocetinostat + Nivolumab Glesatinib + Nivolumab Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Recruiting
NCT02955290 Phase Ib/II CIMAvax-EGF + Nivolumab CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Recruiting
NCT02955758 Phase II Pembrolizumab Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting
NCT02959437 Phase Ib/II Azacitidine + INCB024360 + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Active, not recruiting
NCT02963610 Phase Ib/II lenalidomide + Pembrolizumab Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Terminated
NCT02965885 Phase I TAS-116 A Study of TAS-116 in Patients With Solid Tumors Recruiting
NCT02967133 Phase II Nab-paclitaxel + Nivolumab Nivolumab A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Active, not recruiting
NCT02971501 Phase II Osimertinib Bevacizumab + Osimertinib Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases Recruiting
NCT02974725 Phase I LTT462 + LXH 254 Study of LXH254 and LTT462 in NSCLC Recruiting
NCT02978404 Phase II Nivolumab Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Recruiting
NCT02981108 Phase Ib/II HS-10296 A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Recruiting
NCT02983045 Phase Ib/II NKTR-214 + Nivolumab A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) Recruiting
NCT02983578 Phase II AZD9150 + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Recruiting
NCT02987998 Phase I Cisplatin + Etoposide + Pembrolizumab Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC Recruiting
NCT02991651 Phase I Erlotinib + IRX4204 Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC Recruiting
NCT02998528 Phase III Nivolumab + Ipilimumab Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) Recruiting
NCT03001882 Phase II Nivolumab + Ipilimumab An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03003468 Phase Ib/II Imprime PGG + Pembrolizumab Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 Recruiting
NCT03003962 Phase III Durvalumab Gemcitabine + Cisplatin Carboplatin + Gemcitabine Carboplatin + Pemetrexed Cisplatin + Pemetrexed Paclitaxel + Carboplatin Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer Recruiting
NCT03004105 Phase II MEDI4736 + Selumetinib MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Withdrawn
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC Recruiting
NCT03014648 Phase II Atezolizumab Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03023319 Phase I Bosutinib + Pemetrexed Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting
NCT03023423 Phase Ib/II Atezolizumab + Daratumumab Atezolizumab A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) Active, not recruiting
NCT03023904 Phase II Nivolumab Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads Withdrawn
NCT03037385 Phase I BLU-667 Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Recruiting
NCT03041181 Phase II Docetaxel + Nivolumab Docetaxel Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab Recruiting
NCT03042013 Phase II Naquotinib A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study Withdrawn
NCT03048136 Phase III Nivolumab + Ipilimumab A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) Withdrawn
NCT03048500 Phase II Metformin + Nivolumab Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Recruiting
NCT03049618 Phase II sEphB4-HSA + Pembrolizumab Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Recruiting
NCT03050060 Phase II Nelfinavir + Nivolumab Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Recruiting
NCT03050554 Phase Ib/II Avelumab Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT03052608 Phase III Lorlatinib Crizotinib A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC Recruiting
NCT03054038 Phase I Afatinib + Necitumumab Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer Recruiting
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting
NCT03064854 Phase I Carboplatin + Paclitaxel + PDR001 Cisplatin + Pemetrexed + PDR001 Cisplatin + Gemcitabine + PDR001 Pemetrexed + PDR001 + Cisplatin + Carboplatin PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial) Recruiting
NCT03066206 Phase II Poziotinib Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03071757 Phase I ABBV-368 ABBV-368 + Nivolumab A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03082300 Phase I Naquotinib A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations Terminated
NCT03083808 Phase II Pembrolizumab + Gemcitabine Docetaxel + Pembrolizumab Pemetrexed + Pembrolizumab Pemetrexed Phase II Trial of Continuation Therapy in Advanced NSCLC Recruiting
NCT03086733 Phase II Metformin Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore) Recruiting
NCT03087448 Phase Ib/II Ceritinib + Trametinib Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03087760 Phase II Pembrolizumab Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer Recruiting
NCT03088930 Phase II Crizotinib Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Recruiting
NCT03090737 Phase II Nivolumab Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) Active, not recruiting
NCT03095612 Phase Ib/II Docetaxel + Selinexor Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Active, not recruiting
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Recruiting
NCT03101839 Phase I AZD4785 Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Active, not recruiting
NCT03102242 Phase II Atezolizumab Atezolizumab Immunotherapy in Patients With Advanced NSCLC Recruiting
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Recruiting
NCT03110978 Phase II Nivolumab Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR Recruiting
NCT03121417 Phase II Nivolumab Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer Recruiting
NCT03122717 Phase I Gefitinib + Osimertinib Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Recruiting
NCT03123783 Phase Ib/II APX005M + Nivolumab CD40 Agonistic Antibody APX005M in Combination With Nivolumab Recruiting
NCT03130764 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC Withdrawn
NCT03131037 Phase I AdV-tk + Valacyclovir Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer Recruiting
NCT03131206 Phase Ib/II Alectinib A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Active, not recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03137771 Phase II Docetaxel Pemetrexed Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Recruiting
NCT03138889 Phase I NKTR-214 + Pembrolizumab A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer Recruiting
NCT03148327 Phase Ib/II Durvalumab Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy Recruiting
NCT03156114 Phase I BI 754091 BI 754111 This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Recruiting
NCT03157128 Phase I LOXO-292 Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer Recruiting
NCT03158129 Phase II Nivolumab Nivolumab + Ipilimumab Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection Recruiting
NCT03158883 Phase I Avelumab Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients Recruiting
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Carboplatin + Pemetrexed Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab Carboplatin + nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Recruiting
NCT03164772 Phase Ib/II BI 1361849 + Durvalumab + Tremelimumab Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC Recruiting
NCT03166254 Phase I Pembrolizumab Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer Withdrawn
NCT03166631 Phase I BI 754091 + BI 891065 BI 891065 A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Recruiting
NCT03168464 Phase Ib/II Nivolumab Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Recruiting
NCT03170206 Phase Ib/II Palbociclib Binimetinib Binimetinib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Recruiting
NCT03175224 Phase I CBT-101 CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation Recruiting
NCT03178071 Expanded access Lorlatinib Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations No longer available
NCT03178552 Phase II Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Alectinib A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting
NCT03179436 Phase I MK-1308 + Pembrolizumab Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001) Recruiting
NCT03181308 Phase I Carotuximab + Nivolumab Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Recruiting
NCT03184571 Phase II BGB-324 + Pembrolizumab BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC Recruiting
NCT03191149 Phase II Osimertinib Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Recruiting
NCT03191786 Phase III Atezolizumab Gemcitabine Vinorelbine A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy Recruiting
NCT03195491 Phase III Nivolumab A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) Active, not recruiting
NCT03202940 Phase Ib/II Alectinib + Cobimetinib A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC Recruiting
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Nivolumab + Ipilimumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA) Recruiting
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Recruiting
NCT03217071 Phase II Pembrolizumab Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer Recruiting
NCT03217669 Phase I Epacadostat + Sirolimus Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy Recruiting
NCT03220477 Phase I Guadecitabine + Mocetinostat + Pembrolizumab Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. Recruiting
NCT03223155 Phase I Nivolumab + Ipilimumab Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer Recruiting
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Recruiting
NCT03225664 Phase Ib/II Pembrolizumab Pembrolizumab + Trametinib BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03228186 Phase II Docetaxel + MLN4924 Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Recruiting
NCT03228667 Phase II ALT-803 + Nivolumab ALT-803 + Pembrolizumab QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy Recruiting
NCT03232892 Phase II Trametinib Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer Recruiting
NCT03233724 Phase Ib/II Pembrolizumab The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer Recruiting
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Recruiting
NCT03237377 Phase II Durvalumab + Tremelimumab Durvalumab Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Recruiting
NCT03239340 Phase III Osimertinib A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib Recruiting
NCT03242915 Phase II Carboplatin + Pembrolizumab + Pemetrexed Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs) Recruiting
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Recruiting
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Recruiting
NCT03256136 Phase II Carboplatin + Nivolumab + Pemetrexed Nivolumab + Ipilimumab A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer Recruiting
NCT03257722 Phase Ib/II Idelalisib + Pembrolizumab Pembrolizumab + Idelalisib for Lung Cancer Study Recruiting
NCT03260491 Phase I U3-1402 U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer Recruiting
NCT03262779 Phase II Nivolumab + Ipilimumab Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. Recruiting
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Recruiting
NCT03268057 Phase Ib/II Avelumab + VX15/2503 VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer Recruiting
NCT03270176 Phase I AT-406 + Avelumab A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy Recruiting
NCT03274479 Phase I PBF-1129 PBF-1129 in Patients With NSCLC Recruiting
NCT03275597 Phase I Durvalumab + Tremelimumab Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Recruiting
NCT03285321 Phase II Nivolumab + Ipilimumab Nivolumab Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03286296 Phase I LZM009 LZM009 to Treat Patients With Advanced Solid Tumors Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03292133 Phase II Nazartinib + Gefitinib A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Recruiting
NCT03299088 Phase I Pembrolizumab + Trametinib Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Recruiting
NCT03302234 Phase III Pembrolizumab Ipilimumab + Pembrolizumab Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) Recruiting
NCT03302247 Phase II Nivolumab Gemcitabine + Nivolumab Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy Recruiting
NCT03307759 Phase I Pembrolizumab Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) Recruiting
NCT03308942 Phase II Niraparib Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer Recruiting
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Recruiting
NCT03311672 Phase II Pembrolizumab T-Cell PET Imaging With [18F]F-AraG in Lung Cancer Recruiting
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Recruiting
NCT03318939 Phase II Poziotinib Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation Recruiting
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting
NCT03322540 Phase III Pembrolizumab Epacadostat + Pembrolizumab Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT03322566 Phase III Epacadostat + Pembrolizumab Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Pembrolizumab Plus Epacadostat Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT03325166 Phase II Pembrolizumab Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Recruiting
NCT03326752 Phase I DV281 Phase 1b Dose Escalation and Dose Expansion Trial Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Recruiting
NCT03333343 Phase I Nazartinib + LXH 254 Nazartinib + Trametinib Nazartinib + Gefitinib Nazartinib + Ribociclib Capmatinib + Nazartinib Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC Recruiting
NCT03334617 Phase II AZD9150 + Durvalumab Durvalumab + Olaparib Durvalumab + Vistusertib AZD6738 + MEDI4736 Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy. (HUDSON) Recruiting
NCT03337698 Phase Ib/II Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Atezolizumab + RO6958688 A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) Recruiting
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Recruiting
NCT03348904 Phase III Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Carboplatin + Cisplatin + Epacadostat + Gemzar + Nivolumab + Taxol + Pemetrexed Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer Terminated
NCT03353675 Phase II MVA-MUC1-IL2 vaccine + Nivolumab A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Active, not recruiting
NCT03366766 Phase II Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery Recruiting
NCT03367819 Phase Ib/II Isatuximab Isatuximab + REGN2810 Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies Recruiting
NCT03371992 Phase I Nivolumab Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) Enrolling by invitation
NCT03377023 Phase Ib/II Nivolumab + Ipilimumab Ipilimumab + Nintedanib + Nivolumab Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Recruiting
NCT03380871 Phase I Carboplatin + NEO-PV-01 + poly ICLC + Pembrolizumab + Pemetrexed A Personalized Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer Recruiting
NCT03381274 Phase Ib/II AZD4635 + Oleclumab Oleclumab + Osimertinib MEDI9447 EGFRm NSCLC Novel Combination Study Recruiting
NCT03382899 Phase II Pegilodecakin + Pembrolizumab Pembrolizumab Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) Recruiting
NCT03382912 Phase II Nivolumab + Pegilodecakin Nivolumab Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) Recruiting
NCT03386929 Phase Ib/II Avelumab + Axitinib + Palbociclib Survival Prolongation by Rationale Innovative Genomics (SPRING) Recruiting
NCT03387111 Phase Ib/II Capecitabine nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Recruiting
NCT03391869 Phase III Nivolumab + Ipilimumab Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR) Recruiting
NCT03392246 Phase II Osimertinib + Selumetinib A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Recruiting
NCT03396211 Phase I Apatinib + Nivolumab Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Recruiting
NCT03396497 Phase I LYC-55716 + Pembrolizumab Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Recruiting
NCT03401385 Phase I DS-1062a First-in-human Study of DS-1062a for Advanced Solid Tumors Recruiting
NCT03409458 Phase Ib/II Avelumab + PT-112 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting
NCT03409614 Phase III Ipilimumab + REGN2810 Cemiplimab REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Recruiting
NCT03410043 Phase II Osimertinib Trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients With EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03417037 Phase III BMS-986205 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer Withdrawn
NCT03417882 Phase II GRN-1201 + Pembrolizumab GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC Recruiting
NCT03418532 Phase Ib/II MP0250 MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC Recruiting
NCT03419559 Phase II LN-145 Durvalumab + LN-145 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer Recruiting
NCT03421353 Phase Ib/II AZD9150 + Cisplatin + Durvalumab + Gemcitabine AZD9150 + Carboplatin + Durvalumab + Gemcitabine AZD9150 + Cisplatin + Durvalumab + Fluorouracil AZD9150 + Durvalumab AZD9150 + Carboplatin + Durvalumab + Nab-paclitaxel AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer Recruiting
NCT03425006 Phase II Itacitinib + Pembrolizumab Pembrolizumab and Itacitinib (INCB039110) for NSCLC Recruiting
NCT03425331 Phase II Nivolumab + Ipilimumab Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC Recruiting
NCT03425643 Phase III Cisplatin + Pemetrexed Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Gemcitabine + Cisplatin Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Recruiting
NCT03430063 Phase II Ipilimumab + REGN2810 Cemiplimab A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer Recruiting
NCT03433469 Phase II Osimertinib Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Recruiting
NCT03434418 Phase II Osimertinib A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations Recruiting
NCT03438318 Phase I Atezolizumab + QbG10 Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer Recruiting
NCT03446417 Phase I ZN-e4 A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer Recruiting
NCT03447769 Phase III Canakinumab Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None) Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03455556 Phase Ib/II Atezolizumab + Anetumab ravtansine Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer Recruiting
NCT03455829 Phase Ib/II Osimertinib G1T38 + Osimertinib G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Recruiting
NCT03456063 Phase III Carboplatin + Cisplatin + nab-paclitaxel + Pemetrexed Atezolizumab + Carboplatin + Cisplatin + nab-paclitaxel + Pemetrexed A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) Recruiting
NCT03456076 Phase III Carboplatin + Cisplatin + Gemcitabine + Pemetrexed + Vinorelbine Alectinib A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Participants With ALK Positive Non-Small Cell Lung Cancer Recruiting
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Suspended
NCT03472560 Phase II Avelumab + Axitinib A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) Recruiting
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Recruiting
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Not yet recruiting
NCT03485209 Phase II Tisotumab Vedotin Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting
NCT03502330 Phase I APX005M + Cabiralizumab + Nivolumab APX005M + Cabiralizumab APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Recruiting
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting
NCT03505710 Phase II DS-8201a DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer Recruiting
NCT03509012 Phase I MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide Carboplatin + Cisplatin + Durvalumab + Pemetrexed Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Recruiting
NCT03515629 Phase III Ipilimumab + REGN2810 Pembrolizumab REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Recruiting
NCT03515837 Phase III Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed Carboplatin + Cisplatin + Pemetrexed Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) Recruiting
NCT03516981 Phase II MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495) Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors Recruiting
NCT03520686 Phase II Pembrolizumab ALT-803 + Pembrolizumab QUILT-2.023: A Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC. Recruiting
NCT03520842 Phase II Methotrexate + Regorafenib Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Recruiting
NCT03521154 Phase III Osimertinib A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA) Recruiting
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Active, not recruiting
NCT03527108 Phase II Nivolumab + Ramucirumab Nivolumab Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Not yet recruiting
NCT03535363 Phase I Osimertinib Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC Recruiting
NCT03535740 Phase II Brigatinib A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib Not yet recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03539536 Phase II Telisotuzumab vedotin Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer Recruiting
NCT03559049 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed + Rucaparib Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Recruiting
NCT03563716 Phase II Atezolizumab + MTIG7192A Atezolizumab A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting
NCT03567642 Phase I Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Recruiting
NCT03573947 Phase II Ipilimumab + Nivolumab + Paclitaxel Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705) Recruiting
NCT03574220 Phase I Pembrolizumab Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer Not yet recruiting
NCT03574649 Phase II Carboplatin + Cisplatin + Docetaxel + Paclitaxel NANT non-small cell lung cancer vaccine QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Not yet recruiting
NCT03580694 Phase I Cemiplimab + REGN4659 Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03581487 Phase Ib/II Durvalumab + Selumetinib + Tremelimumab Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer Not yet recruiting
NCT03583086 Phase Ib/II Nivolumab + Vorolanib H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Recruiting
NCT03586453 Phase II Osimertinib Osimertinib In EGFR Mutant Lung Cancer Recruiting
NCT03588039 Phase I Oraxol + Pembrolizumab Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT03589547 Phase II Durvalumab Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Not yet recruiting
NCT03590054 Phase I Abexinostat + Pembrolizumab A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03600701 Phase II Atezolizumab + Cobimetinib Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Recruiting
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting
NCT03611738 Phase I Ceritinib + Docetaxel Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03631706 Phase II M7824 Pembrolizumab M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03631784 Phase II Cisplatin + Pembrolizumab + Pemetrexed Carboplatin + Paclitaxel + Pembrolizumab A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). (KEYNOTE-799) Recruiting
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Recruiting
NCT03634241 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules Recruiting
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Recruiting
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Recruiting
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Recruiting
NCT03645928 Phase II LN-144 + Pembrolizumab LN-145 LN-145 + Pembrolizumab Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Recruiting
NCT03647163 Phase I Pembrolizumab + VSV-hIFNbeta-NIS Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC Not yet recruiting
NCT03647488 Phase II INC280 + PDR001 Docetaxel Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Recruiting
NCT03656718 Phase Ib/II Nivolumab Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03663166 Phase Ib/II Cisplatin + Ipilimumab + Pemetrexed Nivolumab Carboplatin + Ipilimumab + Paclitaxel Cisplatin + Etoposide + Ipilimumab Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03664024 Phase II Pemetrexed + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Cisplatin + Pembrolizumab + Pemetrexed Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) Recruiting
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting
NCT03667820 Phase II Osimertinib Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03681483 Phase I RO5126766 RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Recruiting
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Recruiting
NCT03689855 Phase II Atezolizumab + Ramucirumab Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1) Not yet recruiting
NCT03693300 Phase II Durvalumab A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Not yet recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03707938 Phase I Brigatinib Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Recruiting
NCT03713944 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Recruiting
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Recruiting
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03739710 Phase Ib/II Docetaxel Docetaxel + GSK3359609 Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03745222 Phase III BGB-A317 BGB-A317 + Cisplatin + Etoposide BGB-A317 + Carboplatin + Paclitaxel Cisplatin + Etoposide Paclitaxel + Carboplatin A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) Recruiting
NCT03755102 Phase I Dacomitinib A Study of Dacomitinib in Patients With Metastatic EGFR Mutant Lung Cancer Previously Treated With Osimertinib Recruiting
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Recruiting
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Not yet recruiting
NCT03775486 Phase II Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03778229 Phase II Osimertinib + Savolitinib Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) Recruiting
NCT03784378 Phase Ib/II CEP-32496 Continued Access to RXDX-105 Available
NCT03794544 Phase II Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + IPH2201 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Not yet recruiting
NCT03797391 Phase Ib/II EMB-01 A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors Recruiting
NCT03800134 Phase III Cisplatin + Durvalumab + Gemcitabine Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Carboplatin + Durvalumab + Pemetrexed Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Gemcitabine + Cisplatin A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer Recruiting
NCT03805841 Phase II Tarloxotinib Phase 2 Study of Tarloxotinib in Patients With NSCLC Harboring EGFR Exon 20 Insertion or HER2-activating Mutations (RAIN) Not yet recruiting
NCT03808558 Phase II TVB-2640 Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas Not yet recruiting
NCT03810807 Phase I Dacomitinib + Osimertinib Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer Recruiting
NCT03818776 Phase I Durvalumab Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC Not yet recruiting
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Recruiting
NCT03822351 Phase II Durvalumab Durvalumab + IPH2201 Durvalumab + Oleclumab Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03833154 Phase III Durvalumab Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) Not yet recruiting
NCT03836352 Phase II Cyclophosphamide Pembrolizumab + DPX-Survivac + Cyclophosphamide Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Recruiting